SynAct Pharma AB (SYNACT.ST)
SEK 18.2
(4.48%)
SEK 18.2
(4.48%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -222.7 Million SEK | 39.14% |
| 2022 | -105.7 Million SEK | -38.03% |
| 2021 | -76.61 Million SEK | -145.05% |
| 2020 | -30.9 Million SEK | -28.25% |
| 2019 | -25 Million SEK | 13.21% |
| 2018 | -27.94 Million SEK | -56.57% |
| 2017 | -17.93 Million SEK | -6.89% |
| 2016 | -16.8 Million SEK | -4225.43% |
| 2015 | -388 Thousand SEK | 7.18% |
| 2014 | -418 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -25.7 Million SEK | 71.61% |
| 2024 Q2 | -19.16 Million SEK | 25.44% |
| 2024 Q3 | -24.3 Million SEK | -26.83% |
| 2023 Q2 | -43.49 Million SEK | 25.32% |
| 2023 Q4 | -90.04 Million SEK | -184.12% |
| 2023 Q3 | -31.69 Million SEK | 27.14% |
| 2023 FY | - SEK | -40.99% |
| 2023 Q1 | -58.24 Million SEK | -84.4% |
| 2022 Q2 | -26.41 Million SEK | -18.45% |
| 2022 Q4 | -31.58 Million SEK | -19.37% |
| 2022 FY | - SEK | -38.03% |
| 2022 Q1 | -22.3 Million SEK | 14.73% |
| 2022 Q3 | -26.46 Million SEK | -0.17% |
| 2021 Q4 | -26.15 Million SEK | -25.25% |
| 2021 FY | - SEK | -145.05% |
| 2021 Q3 | -20.88 Million SEK | -33.85% |
| 2021 Q2 | -15.6 Million SEK | -10.99% |
| 2021 Q1 | -14.05 Million SEK | -35.49% |
| 2020 Q3 | -8.88 Million SEK | -53.8% |
| 2020 Q4 | -10.37 Million SEK | -16.8% |
| 2020 FY | - SEK | -28.25% |
| 2020 Q1 | -5.91 Million SEK | 29.92% |
| 2020 Q2 | -5.77 Million SEK | 2.34% |
| 2019 Q2 | -6.39 Million SEK | -26.53% |
| 2019 Q4 | -8.43 Million SEK | -99.68% |
| 2019 FY | - SEK | 13.21% |
| 2019 Q1 | -5.05 Million SEK | 32.46% |
| 2019 Q3 | -4.22 Million SEK | 33.88% |
| 2018 Q3 | -7.33 Million SEK | 24.99% |
| 2018 Q4 | -7.48 Million SEK | -2.02% |
| 2018 FY | - SEK | -56.57% |
| 2018 Q2 | -9.77 Million SEK | -179.16% |
| 2018 Q1 | -3.5 Million SEK | 52.39% |
| 2017 FY | - SEK | -6.89% |
| 2017 Q1 | -3.38 Million SEK | 62.85% |
| 2017 Q4 | -7.35 Million SEK | -251.54% |
| 2017 Q3 | -2.09 Million SEK | 59.04% |
| 2017 Q2 | -5.1 Million SEK | -50.81% |
| 2016 Q2 | -5.56 Million SEK | 0.0% |
| 2016 Q3 | -2.08 Million SEK | 62.6% |
| 2016 Q4 | -9.11 Million SEK | -337.7% |
| 2016 FY | - SEK | -4225.43% |
| 2015 FY | - SEK | 7.18% |
| 2014 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 39.451% |
| Camurus AB (publ) | 562.54 Million SEK | 139.588% |
| Mendus AB (publ) | -97.84 Million SEK | -127.604% |
| Lipum AB (publ) | -37.11 Million SEK | -499.965% |
| NextCell Pharma AB | -40.98 Million SEK | -443.37% |
| Simris Alg AB (publ) | -22.36 Million SEK | -895.846% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -1203.526% |
| Active Biotech AB (publ) | -43.88 Million SEK | -407.442% |
| Amniotics AB (publ) | -27.14 Million SEK | -720.473% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -1466.442% |
| BioArctic AB (publ) | 275.38 Million SEK | 180.868% |
| Cantargia AB (publ) | -284.31 Million SEK | 21.671% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -1037.448% |
| CombiGene AB (publ) | -35.33 Million SEK | -530.237% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | -58.111% |
| Genovis AB (publ.) | 64.57 Million SEK | 444.888% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -93.81% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -501.504% |
| Intervacc AB (publ) | -68.98 Million SEK | -222.849% |
| Kancera AB (publ) | -61.88 Million SEK | -259.839% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -731.501% |
| LIDDS AB (publ) | -39.67 Million SEK | -461.384% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -1739.896% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 809.149% |
| OncoZenge AB (publ) | 7.26 Million SEK | 3164.974% |
| Saniona AB (publ) | -69.69 Million SEK | -219.537% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 29.85% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 21.037% |
| Xintela AB (publ) | -53.47 Million SEK | -316.489% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | -31.143% |
| Ziccum AB (publ) | -20.34 Million SEK | -994.784% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 11135150.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 6.276% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -10606.779% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -1558.112% |
| Corline Biomedical AB | -1.69 Million SEK | -13069.781% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | -28.488% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -306.344% |
| Aptahem AB (publ) | -10 Million SEK | -2124.957% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 2028.314% |
| Fluicell AB (publ) | -25.91 Million SEK | -759.385% |
| Biovica International AB (publ) | -119.5 Million SEK | -86.351% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -427.428% |
| AcouSort AB (publ) | -16.7 Million SEK | -1233.299% |
| Abliva AB (publ) | -93.6 Million SEK | -137.908% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 30.21% |
| 2cureX AB (publ) | -35.13 Million SEK | -533.826% |
| I-Tech AB | 30.34 Million SEK | 833.897% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 68.834% |
| Cyxone AB (publ) | -20.41 Million SEK | -990.923% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -117.369% |
| Biosergen AB | 228 Thousand SEK | 97775.877% |
| Nanologica AB (publ) | -62.11 Million SEK | -258.507% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -407.743% |
| BioInvent International AB (publ) | -312.7 Million SEK | 28.783% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 72075.321% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 530353.101% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 3.852% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -2427.11% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -105.145% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -1841.765% |